Myomo Stock Earnings Reports

Myomo reported Q1 2026 revenue of $10.1M, up 3% year-over-year, driven by a higher average selling price (ASP of $58,800) and stronger international and recurring-channel mix. The company highlighted four strategic pillars for 2026—recurring revenue, market access, operating leverage, and innovation—and said it is making tangible progress on each: launching MyoConnect (referral program) with ~150 rehab facilities referring patients, growing O&P channel revenue (up 79% YoY), expanding international presence (Germany record Q1 revenue, international up 53% YoY), and advancing product and clinical initiatives (new mobile app, ongoing randomized control trial, and MyoPro 3 development). Gross margin improved to 68.2% (up 100 bps YoY); operating expenses were down 1% YoY, producing a narrower operating loss ($3.2M vs. $3.5M prior year) and improved adjusted EBITDA (-$2.3M vs. -$2.8M). Cash and equivalents were $15.7M at quarter end, and cash usage improved to $2.7M in Q1. Management reiterated full-year revenue guidance of $43M–$46M, expects Q2 revenue of $10.3M–$10.8M, and reiterated an operating-leverage target to limit OpEx growth to roughly half the growth rate of revenue for 2026. Key near-term growth drivers are continued ramp of recurring referral sources (MyoConnect and O&P partners), additional payer contracts (notably Elevance/Anthem arrangements), and marketing investments to scale quality lead generation.